Skip to main content
SpringerLink
Log in

G-CSF vs GM-CSF: cost of adverse events makes all the difference

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Rights and permissions

Reprints and permissions

About this article

Cite this article

G-CSF vs GM-CSF: cost of adverse events makes all the difference. Pharmacoecon. Outcomes News 277, 8 (2000). https://doi.org/10.1007/BF03275554

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03275554

Keywords

Search

Navigation